Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 3/20 | 0.59 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.58 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.57 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.55 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.52 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.51 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037167 | 0.89 | SLC2A1 (0.55) | MEP1BMEP1ATAS2R14NPC1RAB9A | |
| SCHEMBL2062287 | 0.85 | CALM1 (0.62) | MEP1BMEP1ATAS2R14CALM1CAMKK2 | |
| SCHEMBL10887096 | 0.81 | MEP1B (0.53) | MEP1BMEP1ATAS2R14CALM1CAMKK2 | |
| SCHEMBL19510228 | 0.80 | MEP1B (0.78) | MEP1BMEP1A | |
| SCHEMBL31260532 | 0.80 | MEP1B (0.78) | MEP1BMEP1A | |
| SCHEMBL2061494 | 0.80 | MEP1B (0.56) | MEP1BMEP1ATAS2R14CALM1CAMKK2 | |
| SCHEMBL13760890 | 0.78 | MEP1B (0.49) | MEP1BMEP1ATAS2R14CALM1CAMKK2 | |
| SCHEMBL2934845 | 0.78 | NPC1 (0.66) | NPC1RAB9AALDH1A1 | |
| SCHEMBL11286611 | 0.77 | ACHE (0.53) | MEP1BMEP1ATAS2R14NPC1RAB9A | |
| SCHEMBL11755258 | 0.77 | MEP1B (0.54) | MEP1BMEP1ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192685-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2004-09-30 | — | — | US | disclosed |
| US-20030220494-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6608203-B2 | Devoid of unwanted side effects | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2001-11-08 | — | — | US | disclosed |
| EP-1113007-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | PFIZER INC. (US) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | MEP1B 826/4885MEP1A 1184/4885TAS2R14 3875/4885 |
| US-20030220494-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | MEP1B 826/4885MEP1A 1184/4885TAS2R14 3875/4885 |
| US-20040192685-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | MEP1B 826/4885MEP1A 1184/4885TAS2R14 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.